Recent pilot studies have suggested a beneficial effect in recent-onset human type 1 diabetes from administration of nondepleting anti-CD3 antibodies or a peptide from heat shock protein 60.[144–146]. Here, HSPD1 is linked to type 1 diabetes mellitus.